Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Estimating rates of true high-grade disease in the prostate cancer prevention trial.

Pinsky P, Parnes H, Ford L.

Cancer Prev Res (Phila). 2008 Aug;1(3):182-6. doi: 10.1158/1940-6207.CAPR-07-0007.

2.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83.

PMID:
17848673
3.

Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.

Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH.

J Natl Cancer Inst. 2007 Sep 19;99(18):1366-74.

PMID:
17848668
4.

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.

PMID:
16912265
5.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality.

Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr.

Cancer. 2005 Apr 1;103(7):1375-80.

6.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079.

PMID:
19328538
7.

[The pathologist's perspective on the PCPT trial].

MoliniƩ V, Allory Y.

Prog Urol. 2008 Apr;18 Suppl 3:S47-52. doi: 10.1016/S1166-7087(08)70514-1. French.

PMID:
18455084
8.
9.

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.

J Urol. 2005 Dec;174(6):2098-104. Review.

PMID:
16280736
10.

High-grade prostate cancer and finasteride.

Lebdai S, Bigot P, Azzouzi AR.

BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Review.

11.
12.

Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.

Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM.

Cancer Prev Res (Phila). 2008 Aug;1(3):174-81. doi: 10.1158/1940-6207.CAPR-08-0092.

13.

Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.

Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83.

14.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
15.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

PMID:
17634486
16.

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.

J Urol. 2005 Sep;174(3):877-81. Erratum in: J Urol. 2005 Nov;174(5):2071.

PMID:
16093979
17.

Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.

Fanning DM, Kay E, Fan Y, Fitzpatrick JM, Watson RW.

BJU Int. 2010 Mar;105(5):631-5. doi: 10.1111/j.1464-410X.2009.08810.x.

18.

Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy.

Numao N, Kawakami S, Yokoyama M, Yonese J, Arisawa C, Ishikawa Y, Ando M, Fukui I, Kihara K.

Eur Urol. 2007 Dec;52(6):1663-8.

PMID:
17240041
19.

The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.

Elliott CS, Shinghal R, Presti JC Jr.

Clin Cancer Res. 2009 Jul 15;15(14):4694-9. doi: 10.1158/1078-0432.CCR-08-2277.

20.

Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

King CR, McNeal JE, Gill H, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):386-91.

PMID:
15145152

Supplemental Content

Support Center